M&T Bank
PTGX icon

M&T Bank’s Protagonist Therapeutics PTGX Stock Holding History

M&T Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Buy
3,984
+126
+3% +$13.2K ﹤0.01% 1211
2026
Q1 		$407K Buy
3,858
+105
+3% +$9.3K ﹤0.01% 1228
2025
Q4 		$328K Buy
+3,753
New +$307K ﹤0.01% 1349

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

M&T Bank's PTGX Position: Q2 2026 in Review

M&T Bank increased its Protagonist Therapeutics (PTGX) stake by 3.3% in Q2 2026, buying an estimated $13.2K and bringing the position to 3,984 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

M&T Bank first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • M&T Bank held 3,984 shares of Protagonist Therapeutics worth $488K as of Q2 2026.
  • M&T Bank bought 126 Protagonist Therapeutics shares in Q2 2026, an estimated $13.2K.
  • Protagonist Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1211 holding.
  • M&T Bank first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.